Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3 study of TACE with durvalumab, tremelimumab, and lenvatinib in locoregional hepatocellular carcinoma
jRCT2011220004Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised, open-label trial of durvalumab, tremelimumab and lenvatinib in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival for Arm A vs Arm C. Started May 2022; status: active, not recruiting.
02
Drugs
durvalumabtremelimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2011220004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220004.